Home PI3K/Akt/mTOR PI3K 억제제 Quercetin (Sophoretin)

연구용

Quercetin (Sophoretin) 플라보노이드 항산화제

제품 번호S2391

채소, 과일 및 와인에 존재하는 천연 플라보노이드인 Quercetin은 재조합 SIRT1의 자극제이자 IC50 2.4-5.4 μM의 PI3K 억제제입니다. Quercetin은 mitophagy, apoptosis 및 보호 autophagy를 유도합니다. 4단계.
Quercetin (Sophoretin) PI3K 억제제 Chemical Structure

화학 구조

분자량: 302.24

바로가기

품질 관리

배치: 순도: 99.01%
99.01

세포 배양, 처리 및 작업 농도

세포주 분석 유형 농도 배양 시간 제형 활성 설명 PMID
Walker 256 Antitumor assay In vivo antitumor activity against rat Walker 256 cells 469554
RBI-1 Function assay In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells, IC50=0.3μM 2066989
MCF-7 Cytotoxicity assay Cytotoxic effect on MCF-7 human breast carcinoma cells, IC50=24μM 8201603
ANN-1 Cytotoxicity assay Cytotoxic effect on v-abl transformed murine ANN-1 cells, IC50=32.5μM 8201603
3T3 Cytotoxicity assay Cytotoxic effect on 3T3 cells, IC50=39.5μM 8201603
WiDr human colon cells Cytotoxicity assay Cytotoxic effect on WiDr human colon cells, IC50=40.2μM 8201603
RBL-1 Function assay In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined, IC50=0.2μM 8254620
HEK293 Function assay Displacement of [125I]AB-MECA binding to human Adenosine A3 receptor expressed in HEK293 cells, Ki=30μM 8576921
L929 Function assay 15 mins Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by crystal violet staining, EC50=20μM 9287415
L929 Function assay 15 mins Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by [methyl-3H]thymidine incorporation assay, EC50=26μM 9287415
L929 Function assay 2 hrs Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality treated with drug after 2 hrs of TNFalpha treatment 9287415
L929 Function assay 2 hrs Potentiation of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality treated with drug after 2 hrs of TNFalpha treatment 9287415
3T3/A31 Growth inhibition assay 10 to 100 ug/mL 72 hrs Growth inhibition of BALB/c mouse cloned 3T3/A31 cells at 10 to 100 ug/mL after 72 hrs by nigrosin assay 10096863
HeLa Function assay TP_TRANSPORTER: inhibition of LTC4 uptake in membrane vesicle from MRP1-expressing HeLa cells, Ki=8.1μM 11306701
RAW264.7 Function assay Inhibition of LPS and INF-gamma-induced NO production in mouse RAW264.7 cells, IC50=26.8μM 15043424
RAW264.7 Function assay Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells, IC50=26.8μM 16378364
HT22 Function assay Inhibition of glutamate-induced oxytosis of mouse hippocampal HT22 cells, EC50=2.98μM 16392814
Jurkat T Function assay Activity against hydrogen peroxide induced DNA damage in Jurkat T cells, IC50=5μM 16392814
BM Antioxidant assay Antioxidant activity in BALB/c mouse BM cells assessed as inhibition of ROS production, IC25=3.5μM 17166721
Sf21 Function assay Inhibition of human recombinant COX2 expressed in insect Sf21 cells by EIA assay, IC50=28.6μM 17378609
LNCaP Function assay Decrease in androgen receptor protein expression in LNCaP cells by Western blotting, EC50=25μM 17383188
SKBR3 Antiapoptotic assay 72 hrs Inhibition of HSP70-mediated antiapoptotic activity in human SKBR3 cells assessed as induction of cell growth arrest after 72 hrs by propidium iodide staining-based flow cytometry 17603540
SKBR3 Antiapoptotic assay 24 hrs Inhibition of HSP70-mediated antiapoptotic activity in human SKBR3 cells assessed as increase in caspase-3 activity after 24 hrs by Western blot analysis 17603540
SKBR3 Antiapoptotic assay 24 hrs Inhibition of HSP70-mediated antiapoptotic activity in human SKBR3 cells assessed as induction of caspase-3 cleavage after 24 hrs by Western blot analysis 17603540
SKBR3 Antiapoptotic assay 24 hrs Inhibition of HSP70-mediated antiapoptotic activity in human SKBR3 cells assessed as induction of PARP cleavage after 24 hrs by Western blot analysis 17603540
BGC823 Function assay 50 uM Effect on cell morphology in human BGC823 cells assessed as chromosomal condensations at 50 uM 17997321
BGC823 Apoptosis assay 50 uM 48 hrs Induction of apoptotic bodies in human BGC823 cells at 50 uM after 48 hrs 17997321
BGC823 Apoptosis assay 50 uM 48 hrs Induction of apoptosis in human BGC823 cells assessed as increase in DNA fragmentation at 50 uM after 48 hrs 17997321
BGC823 Apoptosis assay 100 uM 48 hrs Induction of apoptosis in human BGC823 cells assessed as increase in DNA fragmentation at 100 uM after 48 hrs 17997321
RAW264.7 Function assay 16 hrs Inhibition of LPS and INF-alpha-induced nitric oxide production in mouse RAW264.7 cells after 16 hrs, IC50=25μM 18027905
RAW264.7 Function assay Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells, IC50=26.8μM 18027905
BV2 Function assay Inhibition of LPS-induced NO production in mouse BV2 cells, IC50=29.6μM 18178435
HL60 Antiproliferative assay 30 uM 48 hrs Antiproliferative activity against human HL60 cells at 30 uM after 48 hrs by MTS assay 18258440
Jurkat Function assay 50 ug/mL 1 hr Inhibition of heat-induced HSP70 expression in human Jurkat cells at 50 ug/mL treated for 1 hr before heat induction by Western blot 19296652
HeLa Function assay 50 ug/mL 1 hr Enhancement of HSP27 Ser78 phosphorylation in human HeLa cells at 50 ug/mL treated for 1 hr 19296652
Jurkat Function assay 50 ug/mL 1 hr Inhibition of HSF1 binding to heat shock element DNA assessed as HSF1/HSE complex formation in human Jurkat cells at 50 ug/mL treated for 1 hr before heat induction 19296652
Jurkat Function assay 50 ug/mL 1 hr Inhibition of of heat-induced increase in nuclear HSF1 protein phosphorylation in human Jurkat cells assessed as decrease in protein mobility at 50 ug/mL treated for 1 hr before heat induction by EMSA 19296652
HeLa Function assay 50 ug/mL 1 hr Inhibition of of heat-induced increase in nuclear HSF1 protein phosphorylation in human HeLa cells assessed as decrease in protein mobility at 50 ug/mL treated for 1 hr before heat induction by EMSA 19296652
RAW264.7 Antiinflammatory assay 24 hrs Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess reagent assay, IC50=9.6μM 19555124
MCF7 Function assay 0.5 uM to 10 uM 24 hrs Induction of CYP1A1 expression in human MCF7 cells at 0.5 uM to 10 uM after 24 hrs by RT PCR and DNA electrophoresis 19601638
HeLa Function assay Inhibition of MRP1 transfected in human HeLa cells assessed as inhibition of [3H]LTC4 transport by rapid filtration assay, Ki=2.4μM 19725578
MDCK Antiviral assay Antiviral activity against influenza A virus H1N1 A/PR/8/34 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect, EC50=43.1μM 19729316
RAW264.7 Antiinflammatory assay 24 hrs Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced nitrite accumulation after 24 hrs by Griess reagent method, IC50=11.4μM 19778086
Vero Cytotoxicity assay 3 days Cytotoxicity against african green monkey Vero cells after 3 days by MTT assay, MNCC<20μM 19778089
Vero Cytotoxicity assay 3 days Cytotoxicity against african green monkey Vero cells after 3 days by MTT assay, MNCC<20μM 20092288
RAW264.7 Antiinflammatory assay 24 hrs Antiinflammatory activity against mouse RAW264.7 cells assessed as Inhibition of LPS-induced nitric oxide production after 24 hrs by ELISA, IC50=32.1μM 20121165
Sf9 Function assay Inhibition of rat ecto-5'-nucleotidase expressed in Sf9 cells by capillary electrophoresis method, Ki=0.0453μM 20146483
B16-4A5 Function assay 72 hrs Inhibition of theophylline-stimulated melanogenesis in mouse B16-4A5 cells after 72 hrs, IC50=15μM 20189399
HUVEC Cytoprotective assay Cytoprotective activity against H2O2-induced cell injury in HUVEC cells, EC50=18μM 20621727
HEK293 FS Function assay Inhibition of NOX4 expressed in HEK293 FS cells assessed as H2O2 production by H2O2/Tyr/LPO assay, IC50=0.68μM 20731357
3T3L1 Function assay 10 uM Induction of AMPK phosphorylation in mouse 3T3L1 cells at 10 uM by Western blotting 20822902
3T3L1 Function assay 10 uM Induction of AMPK-mediated ACC phosphorylation in mouse 3T3L1 cells at 10 uM by Western blotting 20822902
3T3L1 Function assay Inhibition of AMPK-mediated adipocyte differentiation in mouse 3T3L1 cells 20822902
3T3L1 Function assay Inhibition of PPAR-gamma-mediated adipocyte differentiation in mouse 3T3L1 cells 20822902
RAW264.7 Antiinflammatory assay 24 hrs Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production after 24 hrs, IC50=34.5μM 20825224
HCT116 Function assay 5 uM 1 hr Cellular uptake in human HCT116 cells assessed a bright fluorescence light at 5 uM after 1 hr by fluorescence microscopic analysis 21090565
MCF7 Function assay 10 uM 5 hrs Cellular uptake in human MCF7 cells assessed as formation of quercetin glucuronide in cell lysates at 10 uM after 5 hrs by HPLC-mass spectrophotometric analysis 21090565
MCF7 Function assay 10 uM 5 hrs Cellular uptake in human MCF7 cells assessed as formation of quercetin sulphate in cell lysates at 10 uM after 5 hrs by HPLC-mass spectrophotometric analysis 21090565
MCF7 Function assay 10 uM 5 hrs Cellular uptake in human MCF7 cells assessed as formation of oxidised quercetin in cell lysates at 10 uM after 5 hrs by HPLC-mass spectrophotometric analysis 21090565
MCF7 Function assay 10 uM 5 hrs Cellular uptake in human MCF7 cells assessed as formation of methylated quercetin in cell lysates at 10 uM after 5 hrs by HPLC-mass spectrophotometric analysis 21090565
RAW264.7 Antiinflammatory assay 1 to 100 uM 24 hrs Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as nitrite level at 1 to 100 uM after 24 hrs by Griess method, Activity=1.38μM 21353543
MDCK Function assay Inhibition of BCRP expressed in MDCK cells using Hoechst 33342 staining, IC50=6.9μM 21354800
MCF-7 MX Function assay Inhibition of BCRP expressed in MCF-7 MX cells using Hoechst 33342 staining, IC50=7.6μM 21354800
HepG2(2.2.15) Cytotoxicity assay 8 days Cytotoxicity against human HepG2(2.2.15) cells after 8 days by MTT assay, CC50=38.1μM 21401115
MDA-MB-231 Function assay 20 uM 30 mins Increase in c-Fos protein expression in human MDA-MB-231 cells at 20 uM within 30 mins by Western blot analysis 21652208
MDA-MB-231 Function assay 20 uM 30 mins Increase in Egr-1 protein expression in human MDA-MB-231 cells at 20 uM within 30 mins by Western blot analysis 21652208
MDA-MB-231 Apoptosis assay 20 uM 12 hrs Induction of apoptosis in human MDA-MB-231 cells assessed as cleaved caspase-7 accumulation at 20 uM after 12 hrs by Western blot analysis 21652208
HepG2 Cytotoxicity assay Cytotoxicity against human HepG2 cells by MTT assay, IC50=30.9μM 21726077
Jurkat Function assay 145 uM 8 hrs Inhibition of heat shock-induced HSP70 expression in human Jurkat cells at 145 uM treated 2 hrs before beat shock challenge measured after 8 hrs by Western blotting 21798748
HepG2 Function assay 24 hrs Inhibition of oleic acid-induced triglyceride over-accumulation in human HepG2 cells incubated for 24 hrs relative to untreated control, IC30=14.9μM 21824690
HepG2 Antioxidant assay 24 hrs Antioxidant activity in human HepG2 cells assessed as reduction of oleic acid-induced ROS generation incubated for 24 hrs by DHCF-DA based fluorimetric assay relative to untreated control, IC30=30.8μM 21824690
MDCK Antiviral assay 4 days Antiviral activity against influenza A virus (A/swine/OH/511445/2007(H1N1)) Oh7 infected in MDCK cells assessed as inhibition of viral replication after 4 days by quantitative RT-PCR, ED50=48.2μM 22115591
HCT116 Growth inhibition assay 48 hrs Growth inhibition of human HCT116 cells overexpressing PI3Kalpha H1047R mutant after 48 hrs by MTT assay, IC50=5.7μM 22212721
HCT116 Growth inhibition assay 48 hrs Growth inhibition of human HCT116 cells after 48 hrs by MTT assay, IC50=6.7μM 22212721
HCT116 Growth inhibition assay 48 hrs Growth inhibition of human HCT116 cells overexpressing PI3Kalpha after 48 hrs by MTT assay, IC50=23μM 22212721
HCT116 Function assay 25 uM 10 mins Inhibition of PI3Kalpha in human HCT116 cells using [32P]ATP at 25 uM after 10 mins 22212721
HCT116 Function assay 25 uM 10 mins Inhibition of PI3Kalpha H1047R mutant in human HCT116 cells using [32P]ATP at 25 uM after 10 mins 22212721
HCT116 Function assay 25 uM Inhibition of PI3Kalpha in human HCT116 cells assessed as inhibition of Akt Ser473 phosphorylation at 25 uM by immunoblot analysis 22212721
HCT116 Function assay 25 uM Inhibition of PI3Kalpha H1047R mutant in human HCT116 cells assessed as inhibition of Akt Ser473 phosphorylation at 25 uM by immunoblot analysis 22212721
human mast cells Function assay Inhibition of SYK in human mast cells assessed as reduction in mast cell degranulation, EC50=35μM 22257213
Huh7.5.1 Antiviral assay 72 hrs Antiviral activity against HCV JFH-1 J399EM infected in Human Huh7.5.1 cells assessed as suppression of viral replication after 72 hrs by EGFP assay, EC50=19.8μM 22445328
HT22 Neuroprotective assay 25 uM 24 hrs Neuroprotective activity against glutamate induced oxidative stress in mouse hippocampal HT22 cells assessed as cell viability at 25 uM after 24 hrs by MTT assay 22624880
22Rv1 Antiproliferative assay Antiproliferative activity against human 22Rv1 cells incubated up to 144 hrs by Coulter particle count and size analyzer, IC50=15.5μM 22789812
RAW264.7 Function assay 50 uM 3 hrs Activation of Nrf2 in mouse RAW264.7 cells assessed as cytosolic accumulation at 50 uM after 3 hrs by Western blotting analysis 23294286
RAW264.7 Function assay 50 uM 3 hrs Activation of Nrf2 in mouse RAW264.7 cells assessed as nuclear accumulation at 50 uM after 3 hrs by Western blotting analysis 23294286
ARPE19 Function assay 20 uM 18 days Inhibition of intracellular A2E photooxidation in human ARPE19 cells at 20 uM after 18 days 23346866
MV4-11 Cytotoxicity assay 72 hrs Cytotoxicity against human MV4-11 cells harboring FLT3 mutation after 72 hrs by tetrazolium based Ez CyTox cell viability assay, GI50=13.1μM 23411073
RS4:11 Cytotoxicity assay 72 hrs Cytotoxicity against human RS4:11 cells harboring wild type FLT3 after 72 hrs by tetrazolium based Ez CyTox cell viability assay, GI50=21.6μM 23411073
HCT116 Cytotoxicity assay 1 to 100 uM 12 hrs Cytotoxicity against human HCT116 cells at 1 to 100 uM after 12 hrs by MTT assay 23434132
MCF7 Cytotoxicity assay 1 to 100 uM 12 hrs Cytotoxicity against human MCF7 cells at 1 to 100 uM after 12 hrs by MTT assay 23434132
HTLA Function assay 20 mins Inhibition of CX3CL1-stimulated CX3CR1 in human HTLA cells pre-incubated for 20 mins measured on day 4 by beta arrestin-recruitment mediated luciferase reporter gene assay, IC50=4.5μM 23437772
HTLA Function assay 20 mins Inhibition of CX3CL1-stimulated CX3CR1 in human HTLA cells pre-incubated for 20 mins measured on day 4 by beta arrestin-recruitment mediated luciferase reporter gene assay, IC50=5.01187μM 23437772
HTLA Function assay 20 mins Inhibition of vasopressin-stimulated vasopressin V2 receptor in human HTLA cells pre-incubated for 20 mins measured on day 4 by beta arrestin-recruitment mediated luciferase reporter gene assay, IC50=6.30957μM 23437772
HTLA Function assay 20 mins Inhibition of vasopressin-stimulated vasopressin V2 receptor in human HTLA cells pre-incubated for 20 mins measured on day 4 by beta arrestin-recruitment mediated luciferase reporter gene assay, IC50=7μM 23437772
HTLA Function assay 20 mins Inhibition of CCL22-stimulated CCR4 in human HTLA cells pre-incubated for 20 mins measured on day 4 by beta arrestin-recruitment mediated luciferase reporter gene assay, IC50=10μM 23437772
HTLA Function assay 20 mins Inhibition of CCL22-stimulated CCR4 in human HTLA cells pre-incubated for 20 mins measured on day 4 by beta arrestin-recruitment mediated luciferase reporter gene assay, IC50=10.2μM 23437772
HTLA Function assay 20 mins Inhibition of vasopressin-stimulated vasopressin V2 receptor in human HTLA cells pre-incubated for 20 mins with Tween-80-treated compound solution measured on day 4 by beta arrestin-recruitment mediated luciferase reporter gene assay, IC50=15.2μM 23437772
HTLA Function assay 20 mins Inhibition of vasopressin-stimulated vasopressin V2 receptor in human HTLA cells pre-incubated for 20 mins with Tween-80-treated compound solution measured on day 4 by beta arrestin-recruitment mediated luciferase reporter gene assay, IC50=15.8489μM 23437772
HTLA Function assay 20 mins Inhibition of vasopressin-stimulated vasopressin V2 receptor in human HTLA cells pre-incubated for 20 mins with centrifuged compound solution measured on day 4 by beta arrestin-recruitment mediated luciferase reporter gene assay, IC50=37.8μM 23437772
HTLA Function assay 20 mins Inhibition of vasopressin-stimulated vasopressin V2 receptor in human HTLA cells pre-incubated for 20 mins with centrifuged compound solution measured on day 4 by beta arrestin-recruitment mediated luciferase reporter gene assay, IC50=39.8107μM 23437772
RAW264.7 Function assay 24 hrs Inhibition of iNOS-mediated nitric oxide production in LPS-stimulated mouse RAW264.7 cells after 24 hrs by Griess reaction analysis, IC50=16.4μM 23517145
RAW264.7 Function assay 24 hrs Inhibition of LPS-induced NO production in mouse RAW264.7 cells after 24 hrs, IC50=1.3μM 23540981
3T3L1 Antiobesity assay 100 uM Antiobesity activity in mouse 3T3L1 cells assessed as reduction of fat accumulation at 100 uM by oil Red O staining-based ELISA 23642481
HT22 Neuroprotective assay 40 uM 3 hrs Neuroprotective activity in mouse HT22 cells assessed as t-BOOH-induced toxicity at 40 uM preincubated for 3 hrs followed by t-BOOH induction measured after 9 hrs by MTT assay 24245939
HT22 Neuroprotective assay 40 uM 3 hrs Neuroprotective activity in mouse HT22 cells assessed as reduction of t-BOOH-induced oxidative stress at 40 uM preincubated for 3 hrs followed by t-BOOH induction measured after 20 hrs by MTT assay 24245939
HepG2 Antioxidant assay 1 hr Antioxidant activity in human HepG2 cells assessed as inhibition of ABAP-induced intracellular peroxyl radical scavenging activity by measuring ROS production measured every 5 mins for 1 hr by absorbance assay, IC50=11μM 24471493
HT22 Neuroprotective assay 24 hrs Neuroprotective activity in mouse HT22 cells assessed as protection against glutamate-induced oxidative damage after 24 hrs by MTT assay, EC50=3.13μM 24602904
HT22 Cytotoxicity assay 24 hrs Cytotoxicity against mouse HT22 cells after 24 hrs by MTT assay, EC50=11.52μM 24602904
RAW264.7 Antiinflammatory assay 10 uM 18 hrs Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha secretion at 10 uM after 18 hrs by sandwich ELISA 24679441
BV2 Antiinflammatory assay Antiinflammatory activity in human BV2 cells assessed as inhibition of LPS-induced nitric oxide production by Griess assay, IC50=10μM 24707938
HT22 Neuroprotective assay 5 uM 48 hrs Neuroprotection against glutamate challenged mouse HT22 cells assessed as reduction in cell viability at 5 uM after 48 hrs by MTT assay 24819955
HT22 Neuroprotective assay 25 uM 24 hrs Neuroprotective activity against glutamate-induced oxidative stress in mouse HT22 cells assessed as reduction of intracellular ROS formation at 25 uM after 24 hrs by MTT assay 24900407
U2OS Function assay 5 hrs Agonist activity at GPR35 receptor in human U2OS cells coexpressing Gal4-VP16-TEV assessed as beta arrestin translocation after 5 hrs by beta lactamase reporter gene assay, EC50=5.93μM 24900447
HT-29 Function assay 10 mins Agonist activity at GPR35 receptor in human HT-29 cells after 10 mins by dynamic mass redistribution assay, EC50=8.02μM 24900447
HT-29 Function assay 10 mins Desensitization of GPR35 receptor in human HT-29 cells assessed as inhibition of zaprinast-induced dynamic mass redistribution after 10 mins, IC50=15.4μM 24900447
HT-29 Function assay 10 mins Partial agonist activity at GPR35 receptor in human HT-29 cells after 10 mins by dynamic mass redistribution assay 24900447
PC12 Neuroprotective assay 5 uM 24 hrs Neuroprotective activity in rat PC12 cells assessed as inhibition H2O2-induced reduction of cell viability at 5 uM after 24 hrs by MTT assay 24941128
HLF1 Function assay 2 to 5 uM 24 hrs Inhibition of H2O2-induced oxidative stress in human HLF1 cells assessed as increase in cell viability at 2 to 5 uM pretreated for 24 hrs followed by addition of 300 uM H2O2 for 2.5 hrs 24996137
HL60 Cytotoxicity assay 72 hrs Cytotoxicity against human HL60 cells after 72 hrs by MTT assay, IC50=47μM 25014747
HT22 Neuroprotective assay 25 uM Neuroprotective activity in mouse HT22 cells assessed as reduction in glutamate-induced cytotoxicity at 25 uM by MTT assay 25059502
RAW264.7 Antiinflammatory assay 3 uM 24 hrs Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as reduction in nitric oxide production at 3 uM after 24 hrs by Griess method based ELISA (Rvb = 52.4 +/- 0.9 uM), Activity=13.5μM 25106885
RAW264.7 Antiinflammatory assay 1.5 uM 24 hrs Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as reduction in nitric oxide production at 1.5 uM after 24 hrs by Griess method based ELISA (Rvb = 52.4 +/- 0.9 uM), Activity=20.8μM 25106885
BV2 Function assay 24 hrs Inhibition of LPS-stimulated NO production in human BV2 cells after 24 hrs by Griess assay, IC50=4.3μM 25127164
HeLa Anticancer assay Anticancer activity against human HeLa cells by HTS assay, IC50=3.56μM 25139569
NCI-H1792 Anticancer assay Anticancer activity against human NCI-H1792 cells by HTS assay, IC50=3.85μM 25139569
LOXIMVI Anticancer assay Anticancer activity against human LOXIMVI cells by HTS assay, IC50=4.65μM 25139569
NCI-H522 Anticancer assay Anticancer activity against human NCI-H522 cells by HTS assay, IC50=5.77μM 25139569
NCI-H157 Anticancer assay Anticancer activity against human NCI-H157 cells by HTS assay, IC50=6μM 25139569
A549 Anticancer assay Anticancer activity against human A549 cells by HTS assay, IC50=6.2μM 25139569
HOP62 Anticancer assay Anticancer activity against human HOP62 cells by HTS assay, IC50=7.52μM 25139569
H460 Anticancer assay Anticancer activity against human H460 cells by HTS assay, IC50=9.62μM 25139569
NCI-H1944 Anticancer assay Anticancer activity against human NCI-H1944 cells by HTS assay, IC50=10.18μM 25139569
M14 Anticancer assay Anticancer activity against human M14 cells by HTS assay, IC50=12.77μM 25139569
H1299 Anticancer assay Anticancer activity against human H1299 cells by HTS assay, IC50=13.6μM 25139569
SKBR Anticancer assay Anticancer activity against human SKBR cells by HTS assay, IC50=16.71μM 25139569
H266 Anticancer assay Anticancer activity against human H266 cells by HTS assay, IC50=16.87μM 25139569
M4E Anticancer assay Anticancer activity against human M4E cells by HTS assay, IC50=21.71μM 25139569
Calu1 Anticancer assay Anticancer activity against human Calu1 cells by HTS assay, IC50=23.58μM 25139569
MDA-MB-231 Function assay 5 uM 16 hrs Inhibition of PMA-stimulated NF-kappaB signaling (unknown origin) expressed in MDA-MB-231 cells at 5 uM incubated for 16 hrs by luciferase reporter gene assay 25190466
MDA-MB-231 Function assay 25 uM Inhibition of basal NF-kappaB signaling in human MDA-MB-231 cells assessed as reduction in MMP9 mRNA expression at 25 uM by quantitative RT-PCR method relative to untreated control 25190466
MDA-MB-231 Function assay 25 uM Inhibition of NF-kappaB signaling in human MDA-MB-231 cells assessed as reduction in PMA-stimulated MMP9 mRNA expression at 25 uM pre-incubated before PMA stimulation by quantitative RT-PCR method relative to untreated control 25190466
MDA-MB-231 Function assay 25 uM Inhibition of basal NF-kappaB signaling in human MDA-MB-231 cells assessed as reduction in COX2 mRNA expression at 25 uM by quantitative RT-PCR method relative to untreated control 25190466
MDA-MB-231 Function assay 25 uM Inhibition of NF-kappaB signaling in human MDA-MB-231 cells assessed as reduction in PMA-stimulated COX2 mRNA expression at 25 uM pre-incubated before PMA stimulation by quantitative RT-PCR method relative to untreated control 25190466
MDA-MB-231 Function assay 25 uM Inhibition of NF-kappaB signaling in human MDA-MB-231 cells assessed as reduction in PMA-stimulated MMP9 mRNA expression at 25 uM pre-incubated before PMA stimulation by quantitative RT-PCR method 25190466
MDA-MB-231 Function assay 25 uM Inhibition of NF-kappaB signaling in human MDA-MB-231 cells assessed as reduction in PMA-stimulated COX2 mRNA expression at 25 uM pre-incubated before PMA stimulation by quantitative RT-PCR method 25190466
MDA-MB-231 Apoptosis assay 3.125 to 25 uM 48 hrs Induction apoptosis in PMA-stimulated human MDA-MB-231 cells assessed as mitochondrial disruption 3.125 to 25 uM after 48 hrs by JC1 staining based fluorescence assay 25190466
RAW264.7 Anti-inflammatory assay 24 hrs Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of lipopolysaccharide-induced nitric oxide production incubated for 24 hrs by Griess reagent based assay, IC50=16.6μM 25245917
HCT116 Cytotoxicity assay 1.25 to 20 uM 96 hrs Cytotoxicity against human HCT116 cells at 1.25 to 20 uM after 96 hrs by MTT assay 25397870
HCT116 Apoptosis assay 20 uM 72 hrs Induction of apoptosis in human HCT116 cells assessed as PARP cleavage at 20 uM after 72 hrs by immunoblotting 25397870
HCT116 Antitumor assay 80 uM 4 days Antitumor activity against human HCT116 cells xenografted in 48 hpf zebrafish embryo assessed as inhibition of cancer cell proliferation at 80 uM treated for 4 days 25397870
C6 Function assay 72 hrs Inhibition of cell proliferation of rat C6 cells assessed as cell viability after 72 hrs by sulforhodamine B assay, IC50=18.38μM 25442304
HCT15 Cytotoxicity assay 72 hrs Cytotoxicity against human HCT15 cells assessed as cell growth inhibition after 72 hrs by MTT assay, IC50=16.35μM 25906385
MCF7 Cytotoxicity assay 72 hrs Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by MTT assay, IC50=20.9μM 25906385
2008 Cytotoxicity assay 72 hrs Cytotoxicity against human 2008 cells assessed as cell growth inhibition after 72 hrs by MTT assay, IC50=21.18μM 25906385
A431 Cytotoxicity assay 72 hrs Cytotoxicity against human A431 cells assessed as cell growth inhibition after 72 hrs by MTT assay, IC50=23.04μM 25906385
BxPC3 Cytotoxicity assay 72 hrs Cytotoxicity against human BxPC3 cells assessed as cell growth inhibition after 72 hrs by MTT assay, IC50=24.12μM 25906385
A375 Cytotoxicity assay 72 hrs Cytotoxicity against human A375 cells assessed as cell growth inhibition after 72 hrs by MTT assay, IC50=25.13μM 25906385
A431 Cytotoxicity assay 72 hrs Cytotoxicity against cisplatin-resistant human A431 cells assessed as cell growth inhibition after 72 hrs by MTT assay, IC50=34.37μM 25906385
C13 Cytotoxicity assay 72 hrs Cytotoxicity against human C13 cells assessed as cell growth inhibition after 72 hrs by MTT assay, IC50=37.62μM 25906385
B16-4A5 Function assay 72 hrs Inhibition of melanogenesis in theophylline-stimulated mouse B16-4A5 cells after 72 hrs by microplate reader analysis, IC50=15μM 25987378
RAW264.7 Anti-inflammatory assay 24 hrs Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production incubated for 24 hrs by Griess reagent based assay, IC50=1.8μM 26143931
BV2 Anti-inflammatory assay 24 hrs Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-stimulated nitric oxide production after 24 hrs by Griess assay, IC50=17.4μM 26327273
LNCAP Cytotoxicity assay 3 days Cytotoxicity against human androgen-dependent LNCAP cells assessed as inhibition of cell viability after 3 days by WST-1 cell proliferation assay, IC50=45.5μM 26341135
BV2 Antineuroinflammatory assay 24 hrs Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-stimulated NO production after 24 hrs by Griess assay, EC50=11μM 26473791
BL21 Function assay 20 uM 15 mins Inhibition of recombinant human N-terminal His6-tagged AKR1B10 expressed in Escherichia coli BL21 cells using all-trans-retinal as substrate at 20 uM incubated for 15 mins by HPLC method 26529431
BV2 Function assay 24 hrs Inhibition of LPS-induced nitric oxide production in human BV2 cells after 24 hrs by Griess assay, IC50=8.7μM 26696523
HT22 Neuroprotective assay 25 uM 24 hrs Neuroprotective activity against glutamate-induced oxycytotic cell death in mouse HT22 cells assessed as cell viability at 25 uM after 24 hrs by MTT assay 26886849
RAW264.7 Anti-inflammatory assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production by Griess assay, IC50=15μM 26928174
HepG2 Antioxidant assay 2.5 hrs Antioxidant activity in human HepG2 cells assessed as decrease in fluorescence level after 2.5 hrs measured every 5 mins for 1 hr by DCFH-DA staining based fluorescence assay, EC50=4.63μM 26974372
RF/6A Antimigratory assay 24 hrs Antimigratory activity in rhesus monkey RF/6A cells measured after 24 hrs by wound assay, IC50=40μM 27015547
RAW264.7 Function assay 24 hrs Inhibition of LPS-induced NO production in mouse RAW264.7 cells after 24 hrs by Griess assay, IC50=15.9μM 27177824
BV2 Antiinflammatory assay 24 hrs Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production incubated for 24 hrs measured after 15 mins by Griess assay, IC50=15.13μM 27335254
PC12 Function assay 5 uM 2 hrs Protective effect against H2O2-induced cell death in rat PC12 cells at 5 uM preincubated for 2 hrs followed by H2O2 addition for 24 hrs by MTT assay 27343850
PC12 Antioxidant assay 2.5 uM 2 hrs Antioxidant activity in rat PC12 cells assessed as decrease of H2O2-induced ROS production at 2.5 uM preincubated for 2 hrs followed by H2O2 addition for 24 hrs by DCFH-DA /DAPI-based fluorescence assay 27343850
LNCAP Antiproliferative assay 3 days Antiproliferative activity against human LNCAP cells after 3 days by WST1 assay, IC50=45.5μM 27476422
BV2 Antineuroinflammatory assay 24 hrs Antineuroinflammatory activity in human BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction, IC50=39.46μM 27623545
N9 Antineuroinflammatory assay 24 hrs Antineuroinflammatory activity in mouse N9 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay, IC50=10.22μM 28073678
Escherichia coli competent cells Function assay overnight Inhibition of amyloid beta (1 to 42) aggregation in Escherichia coli competent cells BL21 (DE3) after overnight incubation by Thioflavin-S steady-state fluorescence assay, IC50=15.3μM 28128562
BV2 Antiinflammatory assay 24 hrs Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitrite production after 24 hrs by Griess assay, IC50=19.11μM 28165740
RAW264.7 Function assay 1 hr Inhibition of LPS-induced NO production in mouse RAW264.7 cells preincubated for 1 hr followed by LPS stimulation measured after 24 hrs by Griess assay, IC50=4.41μM 28427811
LLC-PK1 Renoprotective assay 10 to 100 uM 2 hrs Renoprotective activity in pig LLC-PK1 cells assessed as inhibition of cisplatin-induced damage by measuring increase in cell viability at 10 to 100 uM preincubated for 2 hrs followed by cisplatin addition after 24 hrs by Ez-Cytox reagent based assay 28487074
human red blood cells Antiplasmodial assay 48 hrs Antiplasmodial activity against asexual erythrocyte stage of chloroquine-sensitive Plasmodium falciparum 3D7 infected in human red blood cells after 48 hrs by lactate dehydrogenase assay, IC50=17.54μM 28557449
PC12 Function assay 10 uM Inhibition of human amyloid beta (1 to 42) assessed as neuroprotective activity against amyloid beta (1 to 42)-induced toxicity in rat PC12 cells by measuring reduction in cell viability at 10 uM incubated 15 mins prior to amyloid beta (1 to 42) addition 28559058
T47D Cytotoxicity assay 48 hrs Cytotoxicity against human T47D cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50=11μM 28654265
NCI-H460 Cytotoxicity assay 48 hrs Cytotoxicity against human NCI-H460 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50=12μM 28654265
SK-MEL-2 Cytotoxicity assay 48 hrs Cytotoxicity against human SK-MEL-2 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50=12μM 28654265
LN229 Cytotoxicity assay 48 hrs Cytotoxicity against human LN229 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50=12μM 28654265
A549 Cytotoxicity assay 48 hrs Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50=13μM 28654265
MML1 Cytotoxicity assay 48 hrs Cytotoxicity against human MML1 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50=15μM 28654265
BxPC3 Cytotoxicity assay 48 hrs Cytotoxicity against human BxPC3 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50=16μM 28654265
HT-29 Cytotoxicity assay 48 hrs Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50=18μM 28654265
COLO201 Cytotoxicity assay 48 hrs Cytotoxicity against human COLO201 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50=19μM 28654265
MDA-MB-231 Cytotoxicity assay 48 hrs Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50=20μM 28654265
U87 Cytotoxicity assay 48 hrs Cytotoxicity against human U87 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50=23μM 28654265
LNCAP Antiproliferative assay 3 days Antiproliferative activity against human LNCAP cells after 3 days by WST-1 assay, IC50=45.46μM 28760528
PC12 Neuroprotective assay 10 uM 3 hrs Neuroprotective activity in rat PC12 cells assessed as decrease in H2O2 mediated apoptosis at 10 uM preincubated for 3 hrs followed by H2O2 challenge measured after 24 hrs by MTT assay 28803044
SH-SY5Y Neuroprotective assay 100 uM 12 hrs Neuroprotective activity against H2O2-induced cell death in human SH-SY5Y cells assessed as increase in cell viability at 100 uM pretreated for 12 hrs followed by H2O2 challenge measured after 3 hrs by MTT assay 28988761
BV2 Antiinflammatory assay Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-stimulated nitric oxide production by Griess reagent based spectrophotometric analysis, IC50=16.3μM 29122483
MDA-MB-468 Function assay 6.6 uM Inhibition of human CYP1B1 expressed in MDA-MB-468 cells assessed as potentiation of cisplatin-induced cytotoxicity by measuring cisplatin EC50 at 6.6 uM (Rvb = 6.70+/- 0.7 uM), EC50=1.1μM 29150398
HEK293 Function assay Inhibition of human CYP1B1 expressed in HEK293 cells by fluorescence assay, IC50=2.2μM 29150398
MDA-MB-468 Function assay Inhibition of human CYP1B1 expressed in MDA-MB-468 cells assessed as cell toxicity, IC50=2.2μM 29150398
HEK293 Function assay 20 uM Inhibition of human CYP1A1 transfected in HEK293 cells assessed as protection against CYP1A1 mediated B[a]P toxicity by measuring B[a]P EC50 at 20 uM by MTT assay (Rvb =1.2+/- 0.3 uM), EC50=8.8μM 29150398
HEK293 Function assay Inhibition of human CYP1A expressed in HEK293 cells by fluorescence assay, IC50=9.9μM 29150398
HEK293 Function assay Inhibition of human CYP1A1 transfected in HEK293 cells assessed as cell toxicity, IC50=9.9μM 29150398
BV2 Antiinflammatory assay 24 hrs Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by griess assay, IC50=7.2μM 29303577
DAOY qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells 29435139
A673 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells 29435139
SK-N-MC qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells 29435139
NB-EBc1 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells 29435139
SK-N-SH qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells 29435139
NB1643 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells 29435139
LAN-5 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells 29435139
K562 Cytotoxicity assay 5 days Cytotoxicity against human K562 cells assessed as inhibition of cell growth after 5 days by MTT assay, IC50=2.5μM 29553260
HepG2 Antioxidant assay 60 mins Antioxidant activity in human HepG2 cells assessed as inhibition of ABAP-induced peroxyl radical generation incubated for 60 mins measured for 60 mins by DCFH-DA probe based fluorescence assay, IC50=12μM 29553260
RAW264.7 Cytoprotective assay 1 pM 2 hrs Cytoprotective activity against H2O2-induced oxidative stress in mouse RAW264.7 cells assessed as increase in cell viability at 1 pM incubated for 2 hrs prior to H2O2 addition measured after 24 hrs by MTT assay 29681148
BV2 Antiinflammatory assay 24 hrs Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay, IC50=4.3μM 30119995
BV2 Function assay 24 hrs Inhibition of LPS-induced nitric oxide production in mouse BV2 cells after 24 hrs by Griess assay, IC50=2.4μM 30132670
MCF10A Cytotoxicity assay 3 days Cytotoxicity against human MCF10A cells assessed as decrease in cell viability after 3 days by WST-1 assay, IC50=11.97μM 30165345
PWR-1E Cytotoxicity assay 3 days Cytotoxicity against human PWR-1E cells assessed as decrease in cell viability after 3 days by WST-1 assay, IC50=15.08μM 30165345
LNCAP Antiproliferative assay 3 days Antiproliferative activity against human LNCAP cells after 3 days by WST-1 assay, IC50=45.5μM 30165345
HCT116 Function assay 2.5 uM 30 mins Inhibition of IP6K2 in human [3H]-inositol-labelled HCT116 cells assessed as reduction in insp7 levels at 2.5 uM after 30 mins by HPLC analysis 30624931
HEK293 Function assay 2.5 uM 3.5 hrs Inhibition of IP6K2 in [3H]-inositol-labelled HEK293 cells assessed as reduction in insp7 levels at 2.5 uM after 3.5 hrs by HPLC analysis relative to control 30624931
3T3-L1 Function assay 2.5 uM 3 hrs Activation of AKT activity in mouse 3T3-L1 cells assessed as increase in AKT phosphorylation at T308 residues at 2.5 uM after 3 hrs by Western blot analysis 30624931
3T3-L1 Function assay 1 uM 3 hrs Inhibition of IP6K2 in mouse 3T3-L1 cells assessed as AKT phosphorylation at T308 at 1 uM after 3 hrs by Western blot analysis 30624931
HCT116 Function assay 2.5 uM 3.5 hrs Inhibition of IP6K2 in human [3H]-inositol-labelled HCT116 cells assessed as reduction in insp7 levels at 2.5 uM after 3.5 hrs by HPLC analysis relative to control 30624931
Jurkat Function assay 24 hrs Inhibition of chymotrypsin-like activity of human 26S proteasome in human Jurkat cells assessed as decrease in AMC hydrolysis using Z-Gly-Gly-Leu-AMC as substrate after 24 hrs by fluorescence based method, IC50=2μM 30776692
Jurkat Function assay 2 hrs Inhibition of chymotrypsin-like activity of purified human 20S proteasome expressed in human Jurkat cells assessed as decrease in AMC hydrolysis using Suc-Leu-Leu-Val-Tyr-AMC as substrate incubated for 2 hrs by fluorescence based method, IC50=3.5μM 30776692
CGN Neuroprotective assay 5 to 100 uM 24 hrs Neuroprotective activity in Sprague-Dawley rat CGN cells assessed as protection against H2O2-induced cytotoxicity by measuring increase in cell viability at 5 to 100 uM pre-incubated for 24 hrs before H2O2 stimulation for 24 hrs by MTT assay 30935792
HEK293 Function assay 30 mins Inhibition of human TRPC5 expressed in HEK293 cells assessed as reduction in gadolinium-induced calcium entry after 30 mins by fluo-4 dye based fluorescence assay, IC50=6.5μM 30943030
EPG85-257RDB Function assay 72 hrs Downregulation of ABCB1 gene expression in human EPG85-257RDB cells after 72 hrs by RT-PCR analysis, IC50=12μM 31103904
PC12 Neuroprotective assay 10 uM 3 hrs Neuroprotective activity in rat PC12 cells assessed as protection against H2O2-induced cytotoxicity at 10 uM pre-incubated for 3 hrs before H2O2 addition and measured after 12 hrs by MTT assay 31128990
SH-SY5Y Neuroprotective assay 100 uM 1 hr Neuroprotective activity against H2O2-induced oxidative stress in human SH-SY5Y cells assessed as reduction in ROS generation at 100 uM preincubated for 1 hr followed by DCFH-DA addition for 30 mins and subsequent co-treatment with compound and H2O2 for 3 31158754
HT22 Neuroprotective assay 25 uM 24 hrs Neuroprotection against glutamate-induced cell death in mouse HT22 cells assessed as increase in cell viability at 25 uM measured after 24 hrs by MTT assay 31609115
HT22 Neuroprotective assay 25 uM 24 hrs Neuroprotective activity at mouse HT22 cells assessed as reduction in glutamate-induced oxidative stress by measuring cell viability at 25 uM incubated for 24 hrs by MTT assay 31609608
PANC1 Anti-austerity assay 24 hrs Anti-austerity activity against nutrient-deprived human PANC1 cells assessed as cell death incubated for 24 hrs by WST-8 assay, PC50=21.8μM 31682126
클릭하여 더 많은 세포주 실험 데이터 보기

화학 정보, 보관 및 안정성

분자량 302.24 화학식

C15H10O7

 보관 (수령일로부터)
CAS 번호 117-39-5 SDF 다운로드 원액 보관

용해도

In vitro
배치:

DMSO : 60 mg/mL (198.51 mM)
(수분으로 오염된 DMSO는 용해도를 감소시킬 수 있습니다. 신선하고 무수 DMSO를 사용하십시오.)

Water : Insoluble

Ethanol : Insoluble

몰농도 계산기

질량 농도 부피 분자량
희석 계산기 분자량 계산기

In vivo
배치:

생체 내 제형 계산기 (투명한 용액)

1단계: 아래 정보 입력 (권장: 실험 중 손실을 고려하여 추가 동물 포함)

mg/kg g μL

2단계: 생체 내 제형 입력 (이것은 계산기일 뿐 제형이 아닙니다. 용해도 섹션에 생체 내 제형이 없는 경우 먼저 당사에 문의하십시오.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

계산 결과:

작업 농도: mg/ml;

DMSO 원액 준비 방법: mg 약물 사전 용해 μL DMSO ( 원액 농도 mg/mL, 농도가 해당 약물 배치의 DMSO 용해도를 초과하는 경우 먼저 당사에 문의하십시오. )

생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가μL PEG300, 혼합하고 투명하게 한 다음 추가μL Tween 80, 혼합하고 투명하게 한 다음 추가 μL ddH2O, 혼합하고 투명하게 합니다.

생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가 μL 옥수수 기름, 혼합하고 투명하게 합니다.

참고: 1. 다음 용매를 추가하기 전에 액체가 투명한지 확인하십시오.
2. 용매를 순서대로 추가해야 합니다. 다음 용매를 추가하기 전에 이전 추가에서 얻은 용액이 투명한 용액인지 확인해야 합니다. 와동, 초음파 또는 뜨거운 물 중탕과 같은 물리적 방법을 사용하여 용해를 도울 수 있습니다.

작용 메커니즘

Targets/IC50/Ki
Sirtuin
Src
PKC
PI3Kγ
(Cell-free assay)
2.4 μM
PI3Kδ
(Cell-free assay)
3.0 μM
PI3Kβ
(Cell-free assay)
5.4 μM
시험관 내(In vitro)

Quercetin은 플라보놀로 알려진 식물성 화학 물질 또는 식물성 화학 물질이자 과일, 채소, 잎 및 곡물에서 발견되는 식물 유래 플라보노이드입니다. 또한 보충제, 음료 또는 식품의 성분으로 사용될 수 있습니다. 여러 연구에서 항염증 및 항산화 특성을 가질 수 있으며 광범위한 잠재적 건강상의 이점에 대해 연구되고 있습니다. 이 화합물은 IC50이 2.4 – 5.4 μM인 PI3K 억제제입니다. PI3K 및 Src 키나아제를 강력하게 억제하고 Akt1/2를 약하게 억제했으며 PKC, p38 및 ERK1/2에는 약간 영향을 미쳤습니다.

이 화학 물질은 TNF 유발 LDH% 방출, EC 의존성 호중구의 소 폐동맥 내피 세포(BPAEC) 부착, BPAEC DNA 합성 및 증식을 억제합니다.

생체 내(In vivo)

Quercetin (75 mg/kg)과 2-Methoxyestradiol의 조합은 인간 전립선암 LNCaP 및 PC-3 세포 이종이식 종양 성장을 억제합니다.

LD50: >3000mg/kg (i.g.)

참조
  • [5] https://pubmed.ncbi.nlm.nih.gov/36232461/
  • [6] https://pubmed.ncbi.nlm.nih.gov/36396643/

적용 분야

방법 바이오마커 이미지 PMID
Western blot Bcl-2 / Bax / Bcl-xl p-p53 / p53 / p21 p-JAK1 / p-STAT3 / STAT3 / VEGF Her-2 / p-PI3K / p-Akt / Akt
S2391-WB1
27175602
Growth inhibition assay Cell viability Cell viability
S2391-viability1
27175602

임상시험 정보

(데이터 출처 https://clinicaltrials.gov, 업데이트 날짜 2024-05-22)

NCT 번호 모집 조건 스폰서/협력자 시작일 단계
NCT06003270 Recruiting
Chronic Obstructive Pulmonary Disease|Emphysema|Chronic Bronchitis With Airway Obstruction
Temple University|National Center for Complementary and Integrative Health (NCCIH)|Quercegen Pharmaceuticals
 November 1 2023 Phase 2
NCT04907253 Active not recruiting
Coronary Artery Disease
Montreal Heart Institute
 June 4 2021 Phase 2
NCT04474626 Withdrawn
Sickle Cell Disease|Sickle Cell-Beta0-Thalassemia
Jeffrey Zwicker MD|Quercegen Pharmaceuticals|Dana-Farber Cancer Institute
 December 2020 Phase 2
NCT04063124 Completed
Alzheimer Disease
The University of Texas Health Science Center at San Antonio|Mayo Clinic
 February 14 2020 Phase 1|Phase 2
NCT03989271 Recruiting
Chronic Obstructive Pulmonary Disease
Temple University|National Institutes of Health (NIH)|Quercegen Pharmaceuticals|National Center for Complementary and Integrative Health (NCCIH)
 October 1 2019 Phase 1|Phase 2

기술 지원

취급 설명서

Tel: +1-832-582-8158 Ext:3

다른 문의사항이 있으시면 메시지를 남겨주세요.

이름을 입력해주세요.
이메일을 입력해주세요. 유효한 이메일 주소를 입력해주세요.
저희에게 무엇이든 작성해주세요.